Evolución del consumo de fármacos antipsicóticos en Castilla y León (1990-2001)

dc.contributor.authorJavier García del Pozo
dc.contributor.authorLaura Isusi Lomas
dc.contributor.authorAlfonso Carvajal García‐Pando
dc.contributor.authorIgor Martín Rodríguez
dc.contributor.authorMaría Sáinz-Gil
dc.contributor.authorVictorina García del Pozo
dc.contributor.authorAlfonso Velasco Martín
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:50:18Z
dc.date.available2026-03-22T14:50:18Z
dc.date.issued2003
dc.descriptionCitaciones: 10
dc.description.abstractThe consumption of antipsychotic drugs in Castile and Leon grew by 146% throughout the twelve months studied. The marketing of new atypical antipsychotic drugs and the legal measures related to the deinstitutionalization of mental patients may have played a major role in this increase. The marketing of the new antipsychotic drugs has led to a change in their pattern of use and has give rise to an rise in the direct costs. The consumption of these medications not charged to the National Health System is minor, but not negligible.
dc.identifier.doi10.1590/s1135-57272003000600006
dc.identifier.urihttps://doi.org/10.1590/s1135-57272003000600006
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/48841
dc.language.isoes
dc.publisherMinistry of Health of Spain
dc.relation.ispartofRevista Española de Salud Pública
dc.sourceInstituto Nacional de Salud
dc.subjectAntipsychotic
dc.subjectConsumption (sociology)
dc.subjectChristian ministry
dc.subjectMedicine
dc.subjectHaloperidol
dc.subjectDefined daily dose
dc.subjectRisperidone
dc.subjectPsychiatry
dc.subjectDrug
dc.titleEvolución del consumo de fármacos antipsicóticos en Castilla y León (1990-2001)
dc.typearticle

Files